(R)-[11C]Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus

被引:30
作者
Syvanen, Stina [1 ]
Luurtsema, Gert [2 ]
Molthoff, Carla F. M. [3 ]
Windhorst, Albert D. [3 ]
Huisman, Marc C. [3 ]
Lammertsma, Adriaan A. [3 ]
Voskuyl, Rob A. [1 ,4 ]
de lange, Elizabeth C. [1 ]
机构
[1] Leiden Univ, Div Pharmacol, LACDR, NL-2300 RA Leiden, Netherlands
[2] Univ Groningen, Med Ctr, Dept Nucl Med & Mol Imaging, NL-9700 RB Groningen, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Nucl Med & PET Res, NL-1007 MB Amsterdam, Netherlands
[4] Epilepsy Inst Netherlands Fdn SEIN, NL-2100 AA Heemstede, Netherlands
关键词
POSITRON-EMISSION-TOMOGRAPHY; DRUG EFFLUX TRANSPORTERS; ENDOTHELIAL-CELLS; HIGH-RESOLUTION; UP-REGULATION; RESISTANCE; EPILEPSY; MODEL; INHIBITION; SEIZURES;
D O I
10.1186/1471-2342-11-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Increased functionality of efflux transporters at the blood-brain barrier may contribute to decreased drug concentrations at the target site in CNS diseases like epilepsy. In the rat, pharmacoresistant epilepsy can be mimicked by inducing status epilepticus by intraperitoneal injection of kainate, which leads to development of spontaneous seizures after 3 weeks to 3 months. The aim of this study was to investigate potential changes in P-glycoprotein (P-gp) expression and functionality at an early stage after induction of status epilepticus by kainate. Methods: (R)-[C-11]verapamil, which is currently the most frequently used positron emission tomography (PET) ligand for determining P-gp functionality at the blood-brain barrier, was used in kainate and saline (control) treated rats, at 7 days after treatment. To investigate the effect of P-gp on (R)-[C-11]verapamil brain distribution, both groups were studied without or with co-administration of the P-gp inhibitor tariquidar. P-gp expression was determined using immunohistochemistry in post mortem brains. (R)-[C-11]verapamil kinetics were analyzed with approaches common in PET research (Logan analysis, and compartmental modelling of individual profiles) as well as by population mixed effects modelling (NONMEM). Results: All data analysis approaches indicated only modest differences in brain distribution of (R)-[C-11]verapamil between saline and kainate treated rats, while tariquidar treatment in both groups resulted in a more than 10-fold increase. NONMEM provided most precise parameter estimates. P-gp expression was found to be similar for kainate and saline treated rats. Conclusions: P-gp expression and functionality does not seem to change at early stage after induction of anticipated pharmacoresistant epilepsy by kainate.
引用
收藏
页数:16
相关论文
共 58 条
[1]  
Abramoff M.D., 2004, Biophotonics International, V11, P36
[2]   NEW LOOK AT STATISTICAL-MODEL IDENTIFICATION [J].
AKAIKE, H .
IEEE TRANSACTIONS ON AUTOMATIC CONTROL, 1974, AC19 (06) :716-723
[3]   Where is the evidence that p-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy? [J].
Anderson, Gail D. ;
Shen, Danny D. .
EPILEPSIA, 2007, 48 (12) :2372-2374
[4]  
[Anonymous], 1986, RAT BRAIN STEREO COO, DOI DOI 10.1172/JCI200525102
[5]   Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET [J].
Bankstahl, Jens P. ;
Kuntner, Claudia ;
Abrahim, Aiman ;
Karch, Rudolf ;
Stanek, Johann ;
Wanek, Thomas ;
Wadsak, Wolfgang ;
Kletter, Kurt ;
Mueller, Markus ;
Loescher, Wolfgang ;
Langer, Oliver .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (08) :1328-1335
[6]   Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus [J].
Bankstahl, Jens P. ;
Loescher, Wolfgang .
EPILEPSY RESEARCH, 2008, 82 (01) :70-85
[7]   Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET [J].
Bart, J ;
Willemsen, ATM ;
Groen, HJM ;
van der Graaf, WTA ;
Wegman, TD ;
Vaalburg, W ;
de Vries, EGE ;
Hendrikse, NH .
NEUROIMAGE, 2003, 20 (03) :1775-1782
[8]   Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: Proof-of-concept in a chronic rat model of temporal lobe epilepsy [J].
Bartmann, Hero ;
Fuest, Christina ;
la Fougere, Christian ;
Xiong, Guoming ;
Just, Theresa ;
Schlichtiger, Juli ;
Winter, Petra ;
Boening, Guido ;
Waengler, Bjoern ;
Pekcec, Anton ;
Soerensen, Jonna ;
Bartenstein, Peter ;
Cumming, Paul ;
Potschka, Heidrun .
EPILEPSIA, 2010, 51 (09) :1780-1790
[9]   The multidrug transporter hypothesis of drug resistance in epilepsy:: Proof-of-principle in a rat model of temporal lobe epilepsy [J].
Brandt, Claudia ;
Bethmann, Kerstin ;
Gastens, Alexandra M. ;
Loescher, Wolfgang .
NEUROBIOLOGY OF DISEASE, 2006, 24 (01) :202-211
[10]   MULTIDRUG-RESISTANCE GENE (P-GLYCOPROTEIN) IS EXPRESSED BY ENDOTHELIAL-CELLS AT BLOOD-BRAIN BARRIER SITES [J].
CORDONCARDO, C ;
OBRIEN, JP ;
CASALS, D ;
RITTMANGRAUER, L ;
BIEDLER, JL ;
MELAMED, MR ;
BERTINO, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (02) :695-698